Objectives/Hypothesis: Given the recent emergence of encouraging efficacy data regarding the utility of intralesional glucocorticoid (GC) injection for a variety of vocal fold pathologies, we sought to describe the location and expression pattern of the GC receptors within the vocal folds and quantify the effects of GCs on vocal fold fibroblasts.
INTRODUCTION
Although many have outlined perpetual disappointment regarding the lack of efficacious therapies for patients with vocal fold scar, emerging but limited clinical data may suggest otherwise. A recent retrospective cohort study reviewed outcomes in 34 patients with a variety of vocal fold pathology who underwent intralesional glucocorticoid (GC) injections. Upon further inspection of these data, 16 patients with vocal fold scar and/or nodules, both fibroplastic tissue phenotypes, were included (not all mucosal lesions). Of these 16 patients, 15 improved significantly. The sole failure had chronic laryngitis and keratosis requiring a biopsy. 1 These data concur with those of an earlier report describing a significant decrease in vocal fold nodule size in all patients following intralesional injection of steroids. Furthermore, the nodules completely resolved in 63% of patients in that series. 2 These preliminary efficacy data, combined with the recent trend toward office-based interventions in laryngology, 3 provide a substantial foundation for the systematic investigation regarding localized GC therapy, particularly in patients with vocal fold scar, which has frustrated both clinicians and patients.
GCs are a member of a broad class of hormones and are used as both anti-inflammatory and immunomodulatory agents. Once GCs bind the GC receptor (GCr), which belongs to the nuclear receptor family of liganddependent transcription factors, the activated complex acts upon a number of cells via both transcription and repression of numerous genes. GCs have been used extensively to treat hypertrophic scars and keloids, with intralesional administration yielding a highly variable response rate of 50% to 100% and a recurrence rate of 9% to 50%. [4] [5] [6] [7] [8] [9] [10] The mechanism is thought to be twofold. First, GCs have been shown to be potent anti-inflammatory agents. Second, GCs have been recently shown to decrease collagen and glycosaminoglycan synthesis, in addition to decreasing fibroblast proliferation and increasing hypoxia. 6, [11] [12] [13] [14] [15] [16] GCs have been shown to interact with both transforming growth factor (TGF)-b and 17, 18 In the larynx, these agents have been used in the treatment of various inflammatory diseases including croup, laryngeal edema, and sarcoidosis. [19] [20] [21] [22] In addition, GCs have been shown to be effective in the management of patients with mild Reinke's edema. 23 A recent study attempted to determine the effects of postoperative healing in response to perioperative steroid injection. Interestingly, no quantitative differences were observed with regard to the inflammatory response following injury. GC injection did, however, result in a significant decrease in the rate of collagen deposition up to 7 days following injury. 24 We therefore hypothesize that these outcomes are likely to be beneficial in patients with established fibrosis of the vocal folds and that the effects of GCs are likely related to regulation of extracellular matrix metabolism and fibroblast activation. As such, in the current study, we seek to provide mechanistic information regarding the GCr in the vocal folds and the effects of GCs on vocal fold fibroblast activity.
MATERIALS AND METHODS

Cell Model and Reagents
The HVOX human vocal fold fibroblast cell line was used in the current series of experiments at below passage 20. 
Immunohistochemistry
Three normal adult Sprague-Daley rats were euthanized (no treatment, no injury) and subjected to laryngectomy to immunolocalize baseline GCr status within the vocal fold mucosa. The tissue was processed and embedded in paraffin per standard protocols. Seven-micrometer sections containing the bilateral vocal folds were then subjected to immunohistochemistry for the GCr (1:100 rabbit polyclonal IgG; Santa Cruz Biotechnology, Santa Cruz, CA) with hematoxylin counterstain. Negative controls including the secondary antibody alone were performed (data not shown).
Western Blot
HVOX cells treated for 24 hours with DM at 10, 100, and 200 ng/mL were lysed with M-PER (Mammalian Protein Extraction Solution; Pierce, Rockford, Ill). Equivalent amounts of proteins were separated by 7.5% SDS-PAGE gel and transferred to nitrocellulose membranes (Whatman International Ltd., Maidstone, United Kingdom). The membranes were blocked overnight in 5% nonfat milk and after rinsing were incubated at room temperature for 1 hour with the primary antibody (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA). After washing, blots were subsequently incubated for 1 hour at room temperature with horseradish peroxidase-labelled secondary antibody (Bio-Rad Western Blot Kit; Bio-Rad Laboratories, Hercules, CA). The Bio-Rad Western Blot Kit was then used according to the manufacturer's recommended protocol to detect specifically labeled bands.
Collagen Secretion
Total collagen secreted into the culture medium was quantified using the Sircol Soluble Collagen Assay (Biocolor, Ltd, Belfast, Northern Ireland) as previously described by our laboratory. 26 Near-confluent HVOX, grown in six-well plates, were serum-starved overnight and then treated with media containing 2% serum supplementation and TGF-b (10 ng/mL) and/or DM at 50 and 200 ng/mL for 24 hours and the postculture medium was collected. The manufacturer's recommended protocol was then followed.
Fibroblast Proliferation
The CellTiter 96 Assay (Promega, Madison, WI), a modified MTT assay of cell metabolic activity and viability/cell number, was used to determine the effects of DM on HVOX cells. Subconfluent HVOX cells cultured in 96-well plates were serum-starved for 6 hours and then treated with media containing 2% serum supplementation and DM at 50, 100, and 200 ng/ mL for 48 hours. According to the manufacturer's protocol, 20 lL of the optimized dye solution was added to each well and incubated for 4 hours. Absorbance of solubilized formazan was then read at 570 nm. HVOX were grown to near confluence in six-well plates and serum starved for 24 hours. The cells were then treated with media containing 2% serum supplementation in addition to TGF-b (10 ng/ mL) and/or DM (50 and 200 ng/mL) for 24 hours, and the postculture medium was collected. The manufacturer's recommended protocol was then followed.
Statistical Analyses
All experiments were performed in triplicate, and the data are presented descriptively as the mean 6 standard deviation. One-way analysis of variance was performed for each variable of interest using SPSS 12.0 (SPSS, Inc., Chicago, IL). Tukey honestly significant difference post hoc analyses were performed if a main effect was significant at P < .05.
RESULTS
The GCr is constitutively expressed throughout the vocal fold. As shown in Figure 1A , diffuse staining was observed consistently throughout the rat vocal fold. Dense staining was observed throughout the vocal fold epithelium. Staining was less consistent in the lamina propria. However, positive mesenchymal cell staining was observed as well as focal, punctuate staining of the capillaries (Fig. 1B) .
Human vocal fold fibroblast expression of the receptor decreased in response to DM. Western blot analyses confirmed that human vocal fold fibroblasts constitutively expressed the GCr. As shown in Figure 1C (representative gel), basal GCr expression decreased in response to 24 hours of DM exposure in a dose-dependent manner.
DM limited TGF-b-induced collagen secretion and basal proliferative rate in vocal fold fibroblasts. Consistent with previous findings, TGF-b increased collagen secretion in our cells by approximately 80% ( Fig. 2A ; P < .05). DM at low concentrations decreased this effect significantly and at increasing concentrations completely abrogated TGF-b-induced collagen secretion. In isolation, DM decreased basal levels of collagen secretion to below baseline. Similarly, DM decreased the basal proliferative rate of vocal fold fibroblasts, even at lower concentrations (Fig. 2B ). (Fig. 3B) .
DISCUSSION
Scar is characterized by altered extracellular matrix (ECM) deposition and is often accompanied by a chronic inflammatory component. Therefore, therapies directed at modulating both the inflammatory response as well as ECM metabolism have a high likelihood of proving efficacious. Our data, in combination with recent animal work, suggest that GCs may have an effect on the ECM in the vocal fold. 24 Our data confirm that, in vitro, GCs may be antifibrotic as they limit vocal fold fibroblast activation (i.e., collagen secretion and proliferation). These effects are likely mediated via the GCr, which was localized to the epithelium and lamina propria of the vocal fold. This receptor determines the inherent sensitivity of a cell to GC. Cellular regulation of the GCr is related to adaptation to the hormone environment as well as varying biological requirements. In other systems, GCr levels have been shown to vary significantly due to various factors, including age. 27 The current study only investigated a small number of animals with little age variability, a significant limitation that likely decreases the putative translation of the current findings to the clinic. Fig. 1 . Immunolocalization of the glucocorticoid (GC) receptor in the vocal fold (A) (20Â). Dense, consistent staining was observed in the epithelium. Less positive staining was appreciated within the lamina propria. However, punctuate intracellular positivity was appreciated. Intense staining was also observed in the capillary space (B) (arrows; 40Â). Human vocal fold fibroblasts constitutively express the GC receptor (C) (representative gel), and this expression consistently decreased with increasing concentrations of exogenous dexamethasone.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] Fig. 2 . Dexamethasone (DM) decreased transforming growth factor (TGF)-b-induced collagen secretion in human vocal fold fibroblasts in a dose-dependent fashion (A) (*< .05 relative to control condition; / < .05 relative to TGF-b treatment alone). DM also decreased basal proliferative rate in these cells (B) (*< .05 relative to control; < .05 relative to DM 50).
These receptors are thought to be regulated by both their own ligand (homologous regulation) as well as by other molecules (heterologous regulation). Consistent with our data in human vocal fold fibroblasts, GCs have been shown to be involved in the homologous downregulation of the GCrs. 28 The mechanism of this downregulation is unknown, but it is likely a component of a complex feedback network. In this regard, some discordance in our data is also worth mentioning. As shown in Figure 1 , positive staining for the GCr was only mildly impressive throughout the lamina propria of the vocal folds. However, our fibroblast cell line expressed the receptor protein at relatively high concentrations, potentially suggestive of some intraspecies variability or other experimental confounds. These phenomena warrant further investigation as they may play a significant predictive role in determining the likelihood of favorable patient outcomes.
Immunolocalization of the GCr with high concentration within the epithelial layer may suggest a tertiary, yet favorable, outcome of localized GC therapy. Our laboratory has previously shown that a relatively inert hypertonic challenge to the vocal fold epithelium results in significantly compromised epithelial barrier function. 29 Likewise, chronic phonotrauma and/or surgical injury may also significantly compromise barrier function, placing the underlying lamina propria at risk. 30 Interestingly, numerous studies have shown that GCs improve barrier function via enhanced tight junction protein expression. 31 Improved protection of the lamina propria may also contribute to enhanced healing, potentially shielding the underlying mucosa from the myriad of airborne irritants passing through the upper respiratory tract. Furthermore, we observed significant localization of the GCr to the capillaries within the vocal fold, consistent with other tissues. GCs have been shown to be a potent vasoconstrictor. 32 Perhaps a mechanism for the favorable outcomes shown clinically is this vasoconstriction, which has been previously hypothesized as a mechanism of angiolytic lasers in the context of nonhemorrhagic vocal fold lesions. We hypothesize that all of these factors likely are contributory to favorable clinical outcomes.
DM not only diminished TGF-b-mediated collagen synthesis and fibroblast proliferation, it had a regulatory effect on MMP-1, an enzyme responsible for ECM turnover. Cumulatively, these data may provide some mechanistic insight into the aforementioned animal study and the recently published clinical efficacy data regarding localized injection of steroids for patients with frank vocal fold scar and vocal fold nodules. MMPs are a family of enzymes classified according to their specificity for degrading different components of the ECM. TGF-b has been shown to decrease MMP-1 expression in various tissues, as shown in the current study of vocal fold fibroblasts. The role of MMPs in vocal fold injury and repair is relatively unknown and is based largely on conjecture from other tissues. However, our data suggest that GCs regulate not only ECM synthesis, but also turnover in vocal fold fibroblasts.
Despite the relatively rapid proliferation of innovative therapies of vocal fold scar, a frustrating clinical entity, satisfactory treatments are notably absent. Perhaps GCs that have been around for decades may prove to be a useful and efficacious treatment modality for this otherwise recalcitrant patient population.
CONCLUSIONS
Our data provide mechanistic insight regarding the recently published favorable data regarding the utility of GCs in patients with vocal fold scar, suggesting the GCs alter ECM metabolism in vitro. Although further investigation is warranted, both the accessibility of this class of agents and the amenability to officebased procedures are likely to direct patient care models. 
